Filing Overview
Labcorp Holdings Inc. filed a Form 8-K dated September 22, 2026, under Item 7.01 (Regulation FD Disclosure). The disclosure addresses preliminary 2027–2029 Medicare Clinical Laboratory Fee Schedule payment rates released by the Centers for Medicare & Medicaid Services (CMS) on September 21, 2026.
Business Context and Reporting Period
CMS released preliminary payment rates under the Protecting Access to Medicare Act (PAMA). Labcorp stated that the rates appear to rely on data that is not fully representative of the broader commercial laboratory market and could result in steep annual reimbursement cuts. The company continues to support the bipartisan RESULTS Act as a potential solution.
Financial Metrics and Outlook
- Revenue growth: 5% to 8% compound annual growth for 2026–2029.
- Adjusted operating margin: expansion of 75 to 150 basis points by the end of 2029.
- Adjusted EPS growth: 8.5% to 11.5% compound annual growth.
- Free cash flow: compound annual growth expected to be in line with adjusted earnings growth.
The filing does not provide current-period revenue, GAAP profit, cash flow, debt, liquidity, or reported margin amounts.
Material Changes Versus Prior Disclosure
Labcorp said it had already incorporated anticipated PAMA-related reimbursement pressure into the 2026–2029 long-term outlook presented at its September 10, 2026 Investor Day. The company is reaffirming that outlook despite the preliminary CMS rates. It expects to provide more information on the rates’ effect on 2027 financial guidance when that guidance is announced in February 2027.
Guidance, Risks, and Unusual Items
The outlook includes adjusted, non-GAAP measures. Labcorp stated that it cannot provide forward-looking reconciliations to GAAP without unreasonable effort because certain components cannot be predicted, and actual results could vary materially.
Key risks include changes in healthcare laws and payer policies, adverse governmental or third-party payer actions, customer purchasing decisions, competition, personnel and retention issues, litigation, information technology and data-security failures, geopolitical events, inflation, foreign-exchange fluctuations, weather, potential losses under repurchase agreements, and spin-off-related tax or other items.
The filing contains forward-looking statements and cautions that actual results may differ materially. Labcorp undertakes no obligation to update these statements. The disclosure is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated by reference.
Investor Verification Points
- Verify the final CMS payment rates and how they differ from the preliminary rates.
- Review Labcorp’s February 2027 2027 financial guidance for the quantified PAMA impact.
- Assess whether reimbursement pressure affects the reaffirmed revenue, margin, adjusted EPS, and free-cash-flow targets.
- Review the company’s GAAP results and reconciliations when available, because the long-term targets rely on non-GAAP adjusted measures.
- Monitor legislative developments involving the RESULTS Act and other changes to laboratory reimbursement policy.